Abstract
O‐018: Updated Follow‐up Analysis in the REP 401 Protocol: Treatment of HBeAg Negative Chronic HBV Infection with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α‐2a
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have